Pfizer will launch a large study to test its COVID-19 vaccine for children below 12.
The company said on Tuesday that it has selected a dosing regime for the trial, in which 4,500 children will be enrolled at more than 90 clinical sites in the US, Finland, Poland and Spain.
Pfizer’s vaccine has been authorized for use in children from the age of 12 in Europe, the US and Canada.
A dose of 10 micrograms will be used in the trial among children between 5 and 12 years of age, and 3 micrograms among the age-group of 6 months to five years.
